REPETTO, MATTEO
REPETTO, MATTEO
Universita' degli Studi di MILANO
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers
2024 C. Belli, L. Boscolo Bielo, M. Repetto, E. Crimini, R. Scalia, A. Diana, J. Orefice, L. Ascione, G. Pellizzari, N. Fusco, M. Barberis, B. Daniele, E. Guerini-Rocco, G. Curigliano
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
2024 L. Boscolo Bielo, C. Belli, E. Crimini, M. Repetto, L. Ascione, G. Pellizzari, C. Santoro, V. Fuorivia, M. Barberis, N. Fusco, E.G. Rocco, G. Curigliano
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis
2024 L. Boscolo Bielo, M. Repetto, E. Crimini, C. Belli, E. Setola, G. Parma, N. Fusco, M. Barberis, E. Guerini Rocco, A. Marra, N. Colombo, G. Curigliano
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience
2023 M. Repetto, E. Crimini, L. Boscolo Bielo, E. Guerini-Rocco, L. Ascione, A. Bonfanti, C. Zanzottera, L. Mazzarella, A. Ranghiero, C. Belli, C. Criscitiello, A. Esposito, M.C.P. Barberis, G. Curigliano
High-performance prediction models for prostate cancer radiomics
2023 L.J. Isaksson, M. Repetto, P.E. Summers, M. Pepa, M. Zaffaroni, M.G. Vincini, G. Corrao, G.C. Mazzola, M. Rotondi, F. Bellerba, S. Raimondi, Z. Haron, S. Alessi, P. Pricolo, F.A. Mistretta, S. Luzzago, F. Cattani, G. Musi, O. De Cobelli, M. Cremonesi, R. Orecchia, D. La Torre, G. Marvaso, G. Petralia, B.A. Jereczek-Fossa
A dynamic approach to supply chain reconfiguration and ripple effect analysis in an epidemic
2023 X. Brusset, D. Ivanov, A. Jebali, D. La Torre, M. Repetto
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies
2021 G. Antonarelli, F. Giugliano, C. Corti, M. Repetto, P. Tarantino, G. Curigliano
Precision medicine in breast cancer : From clinical trials to clinical practice
2021 E. Crimini, M. Repetto, P. Aftimos, A. Botticelli, P. Marchetti, G. Curigliano
Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy
2021 M. Repetto, F. Conforti, S. Pirola, M. Calvello, L. Pala, B. Bonanni, C. Catania, G. Curigliano, T. De Pas
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
2021 C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, J.-. Scoazec, L. Lacroix, J.S. Reis-Filho, V. Subbiah, J.F. Gainor, V. Endris, M. Repetto, A. Drilon, A. Scarpa, F. Andre, J.-. Douillard, G. Curigliano
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy
2021 L. Mazzarella, F. Giugliano, E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, E. Nicolo, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, C. Belli, C. Criscitiello, A. Esposito, M. Locatelli, I. Minchella, G. Curigliano
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
2021 M. Repetto, E. Crimini, F. Giugliano, S. Morganti, C. Belli, G. Curigliano
A robust goal programming model for transfer pricing risk hedging: Preliminary results
2019 M. Repetto, D. La Torre, D. Liuzzi